Workflow
微生物新质蛋白
icon
Search documents
董秘说|富祥药业彭云:以合成生物开拓新质生产力 与投资者共享产业发展红利
Xin Lang Cai Jing· 2025-08-06 01:49
Core Viewpoint - The company, Fuxiang Pharmaceutical, is focusing on the development of microbial new protein as a strategic initiative to enhance its market position and contribute to national food security and carbon reduction goals [2][6][9]. Company Overview - Fuxiang Pharmaceutical was established in 2002 and listed on the Shenzhen Stock Exchange in 2015. It is recognized as a national "specialized, refined, distinctive, and innovative" small giant enterprise and a high-tech enterprise in China [4]. - The company specializes in the research, production, and sales of active pharmaceutical ingredients and intermediates, with a recent focus on extending its capabilities into microbial new protein applications [4][5]. Strategic Focus on Microbial New Protein - The company has identified microbial new protein as a key growth area due to its high efficiency, sustainability, and health benefits, including being high in protein, dietary fiber, low in sugar, low in fat, and cholesterol-free [5][6]. - The production of microbial new protein is seen as a solution to the challenges of traditional protein sources, particularly in light of increasing global protein demand and reliance on imported soybean [6]. Market Potential and Growth Projections - The global market for alternative proteins, including microbial fermentation proteins, is projected to reach at least $290 billion by 2035, with microbial proteins expected to capture 22% of this market share [7]. - Fuxiang Pharmaceutical has established itself as a pioneer in the microbial new protein sector, achieving a production capacity of 1,200 tons per year and is currently developing a project with an annual capacity of 200,000 tons [9]. Commitment to Dual Strategy - The company emphasizes the importance of maintaining its core pharmaceutical business while developing new protein lines, ensuring a balanced approach to growth and stability [7][9]. - The strategic focus on microbial new protein aligns with national goals for food security and carbon neutrality, positioning the company as a contributor to sustainable development [6][9].